Oral lenalidomide with rituximab in relapsed or refractory diffuse large cell, follicular and transformed lymphoma: A phase II clinical trial

M. Wang*, N. Fowler, N. Wagner-Bartak, L. Feng, J. Romaguera, S. S. Neelapu, F. Hagemeister, M. Fanale, Y. Oki, B. Pro, J. Shah, S. Thomas, A. Younes, C. Hosing, L. Zhang, K. J. Newberry, M. Desai, N. Cheng, M. Badillo, M. BejaranoY. Chen, K. H. Young, R. Champlin, L. Kwak, L. Fayad

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

151 Scopus citations

Fingerprint

Dive into the research topics of 'Oral lenalidomide with rituximab in relapsed or refractory diffuse large cell, follicular and transformed lymphoma: A phase II clinical trial'. Together they form a unique fingerprint.

Medicine & Life Sciences